casirivimab
Jump to navigation
Jump to search
Indications
- treatment of outpatients with COVID-19 >= 14 years of age >= 40 kg
- prevention of COVID-19 in people with high-risk exposures[3]
- casirivimab + imdevimab appears to be effective against B.1.351 variant from South Africa[4]
* must be administered in combination with imdevimab
Contraindications
- not authorized hospitalized patients or patients who require oxygen therapy for COVID-19
* may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation
Dosage
- 1200 mg or 4000 mg once by intravenous infusion
Mechanism of action
- monoclonal antibody specifically directed against the spike protein of SARS-CoV2
More general terms
Component of
References
- ↑ FDA News Release. Nov 21, 2020 Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19 https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibodies-treatment-covid-19
- ↑ NIH COVID-19 Treatment Guidelimes. Dec 2, 2020 The COVID-19 Treatment Guidelines Panel's Statement on the Emergency Use Authorization of the Casirivimab Plus Imdevimab Combination for the Treatment of COVID-19. https://www.covid19treatmentguidelines.nih.gov/statement-on-casirivimab-plus-imdevimab-eua/
- ↑ 3.0 3.1 Regeneron Pharmaceuticals. Jan 26, 2021 Regeneron Reports Positive Interim Data with REGEN-COV<TM> Antibody Cocktail used as Passive Vaccine to Prevent COVID-19. https://www.prnewswire.com/news-releases/regeneron-reports-positive-interim-data-with-regen-cov-antibody-cocktail-used-as-passive-vaccine-to-prevent-covid-19-301214619.html
Regeneron Phase 3 Prevention Trial Showed 81% Reduced Risk of Symptomatic SARS-CoV-2 Infections with Subcutaneous Administration of REGEN-COV<TM> (casirivimab with imdevimab). Investors & Media, April 12, 2021 https://investor.regeneron.com/news-releases/news-release-details/phase-3-prevention-trial-showed-81-reduced-risk-symptomatic-sars - ↑ 4.0 4.1 NIH COVID-19 Treatment Guidelimes. April 21, 2021 Anti-SARS-CoV-2 Monoclonal Antibodies. https://www.covid19treatmentguidelines.nih.gov/anti-sars-cov-2-antibody-products/anti-sars-cov-2-monoclonal-antibodies/